Weekly Digest – January 2026 Weekly Digest – January 2026 20 January 2026: Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer Eli Lilly announced that the U.S. FDA has […]
Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Sichuan Baili Tianheng Pharmaceutical’s BL-B01D1 marketing application (NDA) has been formally accepted by China’s National Medical Products Administration (NMPA) Sichuan Baili Tianheng Pharmaceutical announced that China’s National […]
Weekly Digest – January 2026 Weekly Digest – January 2026 21 January 2026: Avacta announces U.S. Food and Drug Administration clearance of the Investigational New Drug (IND) application for the second pre|CISION medicine, FAP-Exatecan (AVA6103) Avacta Therapeutics announced that the U.S. […]
